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Objective: Novel biomarkers for monitoring progression in neurodegenerative conditions are needed. Measurement of
microstructural changes in white matter (WM) using diffusion tensor imaging (DTI) may be a useful outcome measure. Here
we report trajectories of WM change using serial DTI in a cohort with behavioral variant frontotemporal dementia (bvFTD).
Methods: Twenty-three patients with bvFTD (12 having genetic mutations), and 18 age-matched control participants
were assessed using DTI and neuropsychological batteries at baseline and 1.3 years later. Baseline and follow-up
DTI scans were registered using a groupwise approach. Annualized rates of change for DTI metrics, neuropsychologi-
cal measures, and whole brain volume were calculated. DTI metric performances were compared, and sample sizes
for potential clinical trials were calculated.
Results: In the bvFTD group as a whole, rates of change in fractional anisotropy (FA) and mean diffusivity (MD) within
the right paracallosal cingulum were greatest (FA: 26.8%/yr, p< 0.001; MD: 2.9%/yr, p5 0.01). MAPT carriers had
the greatest change within left uncinate fasciculus (FA: 27.9%/yr, p< 0.001; MD: 10.9%/yr, p<0.001); sporadic
bvFTD and C9ORF72 carriers had the greatest change within right paracallosal cingulum (sporadic bvFTD, FA:
26.7%/yr, p<0.001; MD: 3.8%/yr, p5 0.001; C9ORF72, FA: 26.8%/yr, p50.004). Sample size estimates using FA
change were substantially lower than neuropsychological or whole brain measures of change.
Interpretation: Serial DTI scans may be useful for measuring disease progression in bvFTD, with particular trajecto-
ries of WM damage emerging. Sample size calculations suggest that longitudinal DTI may be a useful biomarker in
future clinical trials.
ANN NEUROL 2015;77:33–46
The behavioral variant of frontotemporal dementia(bvFTD) is a common cause of early onset dementia
with progressive decline in personality and interpersonal
skills, with gradual emergence of abnormal behaviors
including apathy, obsessionality, and loss of empathy.1
Potential disease-modifying therapies for neurodegenera-
tive disease are now emerging, creating an urgent need to
develop biomarkers with improved accuracy to detect
and monitor disease progression in bvFTD, not least
because a high proportion of cases have a genetic basis,
making presymptomatic intervention a real prospect.2
To date, longitudinal magnetic resonance imaging
(MRI) has been shown to be a useful biomarker in neu-
rodegenerative diseases, given its wide availability, ease of
interpretation, and sensitivity in detecting change (most
typically in brain volume) over time. Previous longitudi-
nal imaging studies of bvFTD have used structural MRI
to measure rates of whole brain and ventricular
change.3–6 A limitation of some of these studies has been
the tendency to measure rates of whole brain atrophy,
rather than regionally based measures. This is significant,
as whole brain techniques may be insensitive to the focal
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losses often seen in bvFTD. In addition, volumetric MRI
may miss microstructural damage and may not provide suf-
ficient sensitivity to detect meaningful change in individuals
with slowly progressive forms of bvFTD, or in presympto-
matic individuals with little macroscopic brain atrophy.2,7
A further problem in tracking progression in
bvFTD is its broad pathological and clinical heterogene-
ity. Predicting underlying pathology on clinical or radio-
logical grounds remains challenging. As such, the use of
current clinical or neuroimaging measures to evaluate
treatments, which will likely target specific molecular
pathologies, is problematic. A number of recent reports
have proposed a common "network-led" framework to
understand how neurodegenerative diseases evolve.8,9
Selective molecular vulnerability of critical brain net-
works such as the Salience Network has been proposed
in bvFTD.10 Following an initial insult to these brain
networks, neurodegeneration may propagate across large-
scale distributed brain networks. The emergence of sensi-
tive neuroimaging techniques, such as diffusion tensor
imaging (DTI), allows us to image the structural connec-
tions within these brain networks in vivo.
This study aims to address these issues by investi-
gating longitudinal white matter change in key white
matter structures in a group of patients with bvFTD. We
also investigate the utility of DTI as a potential bio-
marker for clinical trials by comparing DTI measures of
change with established MRI and neuropsychological
measures and estimate sample size requirements for
potential future clinical trials.
Subjects and Methods
Study Participants
Patients were recruited from 2009 to 2014 as part of a prospec-
tive study tracking disease progression in patients suspected to
have frontotemporal lobar degeneration at the Specialist Cogni-
tive Disorders Clinic, National Hospital for Neurology and
Neurosurgery, London, United Kingdom. Patients who met
current consensus criteria1 for a diagnosis of either probable or
definite bvFTD and had 2 clinical and neuropsychological
assessments and MRI scans (to include both T1-volumetric and
DTI sequences) a minimum of 6 months apart were considered
for study inclusion. All affected individuals provided a DNA
sample for genetic analysis and were screened for mutations in
microtubule-associated protein tau (MAPT), progranulin
(PGRN), and chromosome 9 open-reading frame 72
(C9ORF72) genes. Twenty-three participants were identified as
fulfilling inclusion criteria. Four participants were not included
in the DTI analysis for the following reasons: 2 had significant
artifact on follow-up DTI scans, 1 had an incomplete sequence
due to scanner intolerance, and another had a sphenoid wing
meningioma. Eighteen cognitively normal age- and gender-
matched participants, with no history of psychopathy, stroke,
myocardial infarct, or peripheral vascular disease, underwent the
same test batteries as those with bvFTD. Each study participant
underwent a battery of neuropsychological tests at baseline and
follow-up, including assessments of general intellectual func-
tioning, verbal and visual memory, naming, visuospatial and
visual perception, calculation, and executive function. Social
cognition was assessed using abbreviated versions of the emo-
tion recognition (first 14 items) and social inference (first 9
items) subsets of the Awareness of Social Inference Test.11
MRI Acquisition
Serial MRI scans were performed on the same Siemens Trio
(Siemens, Erlangen, Germany) 3T MRI scanner using a 32-
channel phased array head coil. Two 64-direction DTI sequen-
ces were acquired and averaged using a single-shot, spin-echo
echo planar imaging sequence (55 contiguous axial 2.5mm sli-
ces with 240mm field of view and 96 3 96 matrix, yielding
2.5mm isotropic voxels; repetition time5 6,800 milliseconds,
echo time5 91 milliseconds; b value5 1000 s/mm2). Field
maps, b5 0 s/mm2 images, and a sagittal 3-dimensional mag-
netization prepared rapid gradient echo T1-weighted volumetric
MRI (echo time/repetition time/inversion time5 2.9/2,200/900
milliseconds, dimensions5 256 3 256 3 208, voxel size5 1.1
3 1.1 3 1.1mm) were also acquired. Following visual inspec-
tion for artifacts, field map–based unwarping was applied to
the diffusion-weighted images and they were affine-aligned to
the average b0 image using FLIRT within the FMRIB Software
Library (FSL v5.0.1 reference FSL) to correct for motion and
eddy currents.12 Diffusion-weighted volumes were then com-
bined and tensor fitting completed using CAMINO.13
DTI Registration and Regions of Interest
Ascertainment
Registration of DTI images was carried out using a previously
published method carried out on the same magnetic resonance
scanner (see Fig 1 for an overview).14 This method has also
been shown to have good reproducibility of DTI metrics when
performing repeated DTI measurements on the same subject.
Tensor-based registration was performed using the DTI-TK
(http://dti-tk.sourceforge.net) software package,15 which uses
the full diffusion tensor information to drive the registration
and improve the alignment of white matter structures.16
Within-subject DTI templates are created using an iterative
process of initial rigid registration, followed by nonlinear regis-
tration. This process is repeated using the intrasubject templates
to create an intersubject groupwise template. A single deforma-
tion field was estimated for each original image to the group-
wise template by combining the deformations fields from the
intra- and intersubject registration stages. This facilitates a sin-
gle interpolation of the original DTI images to the intersubject
groupwise mean. Maps of fractional anisotropy (FA), mean dif-
fusivity (MD), axial diffusivity (AX), and radial diffusivity
(RD) were then created for each registered diffusion tensor
image in the groupwise space.
To derive anatomically specific measures of diffusion
change, the ICBM-DTI-81 white matter atlas was linearly and
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nonlinearly registered to the final FA template using FLIRT and
FNIRT from FSL, and regions of interest, which included genu,
body, and splenium of the corpus callosum, bilateral uncinate
fasciculus, parahippocampal (ventral) cingulum bundle, paracal-
losal (dorsal) cingulum bundle, corticospinal tract, superior cere-
bellar peduncle, and fornix, were located using the white matter
labels. Binary masks of each region were generated using a
threshold of 50% on the white matter probability map with a
further 1mm erosion around the boundary of each mask to pro-
vide high anatomical specificity. A visual inspection of each mask
was performed to ensure appropriate coverage. The uncinate fas-
ciculus did not undergo erosion, as this would have limited the
mask size, reducing sensitivity to detect change in this tract.
Volumetric Analysis
Volumetric image analysis was performed using a rapid, semiauto-
mated segmentation technique yielding a brain region separated
from surrounding cerebrospinal fluid, skull, and dura. Serial scans
were aligned and volume change calculated directly using the bound-
ary shift integral (BSI).17 BSI-derived whole brain volume changes,
the brain boundary shift integral (BBSI), were expressed as annual-
ized volume change as a percentage of the baseline brain volume.
Statistical Analysis and Sample Size Estimates
Statistical analyses were carried out using Stata 12 (Statacorp,
College Station, TX). Cross-sectional DTI metric data were
compared between disease and cognitively normal groups using
a linear regression model adjusting for age, gender, and disease
duration. Mixed-effects linear regression models with random
intercept were used to compare longitudinal change between
groups for each DTI metric and region of interest, adjusting
for age, gender, and disease duration. For longitudinal models
log of each DTI metric was the dependent variable, with disease
group, time from baseline scan in years, and interaction
between disease group and time included to provide estimates
of differences in the rate of change as a percentage per year.
FIGURE 1: Overview of processing pipeline for longitudinal diffusion tensor imaging analysis. AX5axial diffusivity; DT5diffu-
sion tensor; FA5 fractional anisotropy; GW5group-wise; MD5mean diffusivity; RD5 radial diffusivity. [Color figure can be
viewed in the online issue, which is available at www.annalsofneurology.org.]
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This methodology was also used to compare cross-sectional and
longitudinal neuropsychological data between groups.
To determine the accuracy, sensitivity, and specificity of each
DTI metric in classifying individual participants into separate
groups (bvFTD or control), receiver operating characteristic curves
were constructed using either raw DTI metric data (for baseline
measurement) or the estimated mean difference in the rate of change
for each diffusivity metric (for longitudinal measurement). Areas
under the curve (AUCs) were calculated for regions of interest,
which were significantly different when compared with controls.
Estimation of sample sizes for future trials were calculated
(using Stata) with 80% power and 5% 2-tailed significance
using the mean difference in the rate of change between groups
for each DTI metric and neuropsychological score, and whole
brain atrophy, using the BBSI, to detect a 20, 30, 40, and 50%
reduction in yearly change.
Results
Demographics, Neuropsychological
Performance, and Changes in Whole Brain
Volume
Demographic and volumetric imaging characteristics of
study participants are shown in Table 1; of the 23
bvFTD patients, 9 had apparently sporadic bvFTD, hav-
ing no family history of bvFTD and a negative test for rele-
vant genetic mutations; 8 patients had mutations in MAPT
(5 exon 10 116 mutations, 2 R407W mutations, and 1
P301L mutation); 4 patients had a C9ORF72 mutation.
Patients and cognitively normal participants were matched
for age, gender, and total intracranial volume. Compared
with cognitively normal participants, those with bvFTD had
significantly lower Mini-Mental State Examination scores
(p< 0.01) and whole brain volumes (p 0.001) at baseline
and follow-up. Rates of atrophy were greatest (p5 0.002) in
the bvFTD group, with the highest rate of volume loss
occurring in those withMAPTmutations (p5 0.001).
Neuropsychological performance at baseline and
longitudinally is shown in Table 2 (see Supplementary
Table 1 for bvFTD subgroups). Compared with cogni-
tively normal participants, at baseline, those with bvFTD
had significantly poorer performance on tests of general
intellect, recognition memory, naming, object perception,
executive function, emotion recognition, and social infer-
ence. Longitudinally, the greatest change observed in the
bvFTD group was a 30.4% decline in score on the
graded naming test compared with a 2% increase in cog-
nitively normal participants (p< 0.001).
TABLE 1. Study Participants’ Clinical and Imaging Characteristics
Characteristic Controls,
n5 18
MAPT,
n5 8
C9ORF72,
n5 4
Sporadic,
n5 11
All bvFTD,
n5 23
pa
Mean SD Mean SD Mean SD Mean SD Mean SD
Age at baseline, yr 61.3 9.5 56.7 8.9 64.1 8.7 68.8 8.4 63.8 10.0 0.4
Disease duration
at baseline, yr
5.2 5.4 9.3 5.9 6.8 4.7 6.7 5.1 N/A
Sex, M/F, No. 12/6 5/3 4/0 10/1 18/5 0.7b
Interscan interval, yr 1.4 0.5 1.3 0.5 1.0 0.1 1.2 0.5 1.2 0.4 0.2
Education, yr 16.55 1.42 14.6 3.9 15.5 4.1 16.6 3.0 15.5 3.5 0.3
MMSE baseline 29.7 0.6 25.5 4.2 2.5 6.9 25.8 3.4 25.3 4.2 <0.001c
MMSE follow-up 29.7 0.5 26.3 5.4 25.3 4.3 25.1 3.5 25.6 4.2 0.002c
TIV, ml 1,572 134 1,503 135 1,649 135 1,565 123 1,556 137 0.6
Whole brain volume,
baseline, ml
1,193 91 1,047 88 1,192 93 1,026 48 1,070 95 0.001
Whole brain volume,
follow-up, ml
1,184 95 1,028 95 1,167 93 1,001 37 1,047 95 <0.001
BBSI, ml/yr 5.2 6.7 15.7 6.7 14.4 17.8 14.8 10.6 15.2 10.4 0.002
aLinear regression comparing controls with all bvFTD subjects.
bFisher exact test.
cWilcoxon rank sum test.
BBSI5 brain boundary shift integral; bvFTD5 behavioral variant frontotemporal dementia; C9ORF725 chromosome 9 open-
reading frame 72; F5 female; M5male; MAPT5microtubule-associated protein tau; MMSE5Mini-Mental State Examination;
SD5 standard deviation; TIV5 total intracranial volume.
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Cross-Sectional DTI Results
Cross-sectional DTI metric data for FA and MD are
shown in Table 3 (see Supplementary Table 2 for RD
and AX). At baseline, compared with cognitively normal
participants, bvFTD patients as a group had significantly
lower (p 0.02) FA and increased MD within the body
of the corpus callosum, bilateral uncinate fasciculus, and
right parahippocampal cingulum, and additionally
TABLE 3. Baseline Diffusion Tensor Imaging Metric Data for Individual White Matter Regions of Interest for
Control Participants and Patients
Regions of Interest Controls,
n5 18
bvFTD,
n5 19
%
Difference 95% Confidence
Interval
pa
Mean SD Mean SD
FA
Genu corpus callosum 0.74 0.03 0.73 0.04 0.34 22.64 3.31 0.8
Body corpus callosum 0.70 0.04 0.66 0.04 24.87 28.68 21.07 0.01
Splenium corpus callosum 0.79 0.02 0.78 0.02 21.27 23.15 0.61 0.2
Cingulum (paracallosal) R 0.63 0.05 0.58 0.06 24.26 29.25 0.73 0.09
Cingulum (paracallosal) L 0.60 0.04 0.55 0.07 22.25 27.08 2.59 0.4
Cingulum (parahippocampal) R 0.43 0.04 0.38 0.04 25.77 29.59 21.96 0.004
Cingulum (parahippocampal) L 0.45 0.04 0.40 0.04 25.26 29.19 21.33 0.01
Fornix 0.59 0.03 0.57 0.04 21.91 24.21 0.40 0.1
Uncinate fasciculus R 0.48 0.05 0.43 0.04 24.65 28.62 20.67 0.02
Uncinate fasciculus L 0.48 0.04 0.43 0.07 26.24 211.32 21.16 0.02
Corticospinal tract R 0.62 0.05 0.62 0.07 21.45 27.15 4.25 0.6
Corticospinal tract L 0.65 0.04 0.64 0.05 22.15 26.12 1.81 0.3
SCP R 0.79 0.05 0.78 0.06 22.24 27.21 2.72 0.4
SCP L 0.79 0.04 0.77 0.05 22.88 27.19 1.42 0.2
MD, 1023mm2/s
Genu corpus callosum 0.76 0.04 0.80 0.08 0.29 24.81 5.40 0.9
Body corpus callosum 0.80 0.06 0.88 0.08 8.66 2.55 14.76 0.01
Splenium corpus callosum 0.74 0.03 0.77 0.05 3.80 20.12 7.72 0.06
Cingulum (paracallosal) R 0.72 0.04 0.72 0.05 1.64 22.48 5.76 0.4
Cingulum (paracallosal) L 0.71 0.04 0.73 0.05 0.47 23.49 4.43 0.8
Cingulum (parahippocampal) R 0.74 0.03 0.85 0.12 9.32 1.49 17.15 0.02
Cingulum (parahippocampal) L 0.73 0.04 0.83 0.11 10.63 3.09 18.17 0.007
Fornix 0.84 0.06 0.91 0.10 5.44 20.09 10.97 0.05
Uncinate fasciculus R 0.70 0.04 0.83 0.13 13.50 4.81 22.19 0.003
Uncinate fasciculus L 0.71 0.03 0.85 0.18 14.87 2.65 27.10 0.02
Corticospinal tract R 0.66 0.06 0.67 0.09 1.84 25.28 8.96 0.6
Corticospinal tract L 0.62 0.05 0.62 0.09 2.45 24.32 9.22 0.5
SCP R 0.85 0.07 0.87 0.09 5.41 21.96 12.78 0.1
SCP L 0.78 0.07 0.80 0.07 4.22 22.29 10.72 0.2
aLinear regression comparing bvFTD with controls after adjusting for age, gender, and disease duration.
vFTD5 behavioral variant frontotemporal dementia; FA5 fractional anisotropy; L5 left; MD5mean diffusivity; R5 right;
SCP5 superior cerebellar peduncle; SD5 standard deviation.
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increased MD in left parahippocampal cingulum. In
MAPT mutation carriers, FA was 6.4% (95% confidence
interval [CI]5211 to 22%; p< 0.009) lower in right
parahippocampal cingulum compared with controls,
whereas MD was 17.7% higher in right uncinate fascicu-
lus (95% CI5 9.0 to 27%; p< 0.001) and 9.4% higher
in right parahippocampal cingulum (95% CI5 2.1 to
16.6%, p5 0.01). In sporadic bvFTD, FA was 10.3%
lower in left uncinate fasciculus (95% CI5218.2 to
22.5%; p5 0.01) and 6.7% lower in right parahippo-
campal cingulum (95% CI5212.7 to 20.6%;
p5 0.03) compared with controls, whereas MD was
31% higher in left uncinate fasciculus (95% CI5 13.5
to 50%; p5 0.002) and 15% higher in right parahippo-
campal cingulum (95% CI5 6.1 to 24%, p5 0.002). In
C9ORF72 mutation carriers, FA was 11% lower in both
right and left superior cerebellar peduncle (right: 95%
CI5221.1 to 21.0%, p5 0.03; left: 95% CI5220.1
to 21.9%, p5 0.02) compared with controls.
Longitudinal DTI Changes in bvFTD
Rates of change for each region of interest and diffusivity
metric are shown in Table 4 and Figures 2 and 3 (see
Supplementary Table 3 for RD and AX). Longitudinally,
compared with cognitively normal participants, bvFTD
patients as a group had the largest reductions in FA
within bilateral paracallosal cingulum (right: 26.8%/yr,
95% CI528.0 to 22.7%, p< 0.001; left, 25.5%/yr,
95% CI526.9 to 22.2%, p< 0.001) and bilateral
uncinate fasciculus (right, 24.2%/yr, 95% CI528.7 to
22.7%, p< 0.001; left: 23.1%/yr, 95% CI528.6 to
21.5%, p5 0.005). The largest increases in MD were
within bilateral uncinate fasciculus (right: 5.1%/yr, 95%
CI5 2.3 to 8.0%, p< 0.001; left: 6.2%/yr, 95%
CI5 1.6 to 10.8%, p5 0.01;) and bilateral parahippo-
campal cingulum (right: 4.3%/yr, 95% CI5 1.6 to
7.1%, p5 0.002; left, 5.0%/yr, 95% CI5 1.1 to 9.0%,
p5 0.01).
Longitudinal DTI Changes in bvFTD Subgroups
Rates of change for each region of interest and diffusivity
metric are shown in Table 4 (see Supplementary Table 3
for RD and AX). Compared with cognitively normal
participants, the largest reductions in FA were within
bilateral uncinate fasciculus (right: 27.2%/yr, 95%
CI529.7 to 24.7%, p< 0.001; left: 27.9%/yr, 95%
CI5212.0 to 23.7%, p< 0.001) in MAPT mutation
carriers; bilateral paracallosal cingulum bundle (right:
26.7%/yr, 95% CI5210.0 to 23.4%, p< 0.001; left:
25.6%/yr, 95% CI528.3 to 22.8%, p< 0.001) in
those with sporadic bvFTD, and in right paracallosal
cingulum bundle (6.8%/yr, 95% CI5211.3 to 2.2%,
p5 0.004) in C9ORF72 mutation carriers. Compared
with cognitively normal participants, the largest increases
in MD were in bilateral uncinate fasciculus (right: 6.7%/
yr, 95% CI5 3.7 to 9.6%, p< 0.001; left: 10.9%/yr,
95% CI5 5.2 to 16.5%, p< 0.001) in MAPT mutation
carriers, bilateral paracallosal cingulum bundle (right:
3.8%/yr, 95% CI5 1.5 to 6.0%, p5 0.001; left: 3.4%/
yr, 95% CI5 0.8 to 6.1%, p5 0.01) in sporadic
bvFTD, and left uncinate fasciculus (6.0%/yr, 95%
CI5 0.8 to 11.2%, p5 0.02) in C9ORF72 mutation
carriers.
Cross-Sectional and Longitudinal DTI Metric
Sensitivity and Specificity
AUC data indicated that classification of control and bvFTD
groups cross-sectionally were best achieved using RD, meas-
ured within the right uncinate fasciculus (AUC5 0.86, spe-
cificity5 94%, sensitivity5 68%), followed by MD
(AUC5 0.83, specificity5 89%, sensitivity5 74%), FA
(AUC5 0.79, specificity5 67%, sensitivity5 84%), and
AX (AUC5 0.75, specificity5 83%, sensitivity5 74%).
Classification of control and bvFTD groups longitudinally
were best achieved using FA change, measured within the
right cingulum bundle (AUC5 0.79, specificity5 94%,
sensitivity5 63%), followed by MD (AUC5 0.77, specific-
ity5 89%, sensitivity5 68%), and RD (AUC5 0.76, spe-
cificity5 100%, sensitivity5 58%), with AX performing
less favorably (AUC5 0.53, specificity5 67%,
sensitivity5 47%).
Sample Size Estimations
Sample sizes required for future clinical trials were calcu-
lated using annualized change score in 3 potential out-
come measures: whole brain atrophy (using BBSI),
change in graded naming test, and DTI change within
either right paracallosal cingulum or right uncinate fasci-
culus (chosen on the basis of statistical significance).
Sample size estimates corrected for control rates of
change are displayed in Table 5. Sample size estimates
based on changes in FA were smaller than sample size
estimates based on other outcome measures.
Discussion
This study is among the first to demonstrate the feasibil-
ity of carrying out longitudinal DTI in patients with
bvFTD. Compared with previous DTI studies, we used
what we believe to be an improved approach for DTI
spatial normalization, which enforces longitudinally and
cross-sectionally consistent and accurate region of interest
segmentations, thus reducing potential noise within the
DTI data set, which is often a significant methodological
problem. Using these improved DTI methods, we (1)
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report both core and mutation-specific patterns of white
matter change in bvFTD; and (2) demonstrate that lon-
gitudinal DTI is a feasible outcome measure for clinical
trials, requiring smaller sample sizes than other more
conventional outcome measures.
We found that decreasing FA and increasing MD
within bilateral paracallosal cingulum bundle, body of
the corpus callosum, and bilateral uncinate fasciculus was
the most consistent finding across all bvFTD groups.
These findings are in line with a number of cross-
sectional DTI studies in bvFTD.18–22 In terms of biolog-
ical validity, the cingulum bundle is a key association
tract linking anterior cingulate and prefrontal cortices
and likely underpins executive processes. It is of interest
that the greatest cross-sectional differences in the cingu-
lum were within the parahippocampal subdivision. This
suggests this ventral subdivision of the cingulum, linking
structures within the limbic system such as hippocampus
and posterior cingulate cortex, is involved early in the
disease process, and may account for some of the more
subtle changes in general intellectual function seen in
early bvFTD.23 However, over time the paracallosal cing-
ulum, linking cingulate and prefrontal cortices and over-
lapping with the functionally relevant Salience
Network,10 showed greater disease progression. These
longitudinal imaging changes may be associated with the
clinical evolution of bvFTD, with progressive disintegra-
tion of social cognition and executive skills such as
response inhibition and set shifting.24,25 In addition,
alterations to the cingulum bundle have been found in
Alzheimer disease26 and several psychiatric disorders.27
The corpus callosum is the major commissure integrating
right and left hemispheric cognitive processes. Damage
to the corpus callosum has been linked to a range of
abnormal social behaviours28 and may lead to disconnec-
tion between brain regions that integrate semantic knowl-
edge (left hemisphere) with emotional meaning (right
hemisphere), impacting on the ability to interpret para-
linguistic information and situational context, a common
feature in bvFTD.29 The uncinate fasciculus has been
implicated in cross-sectional studies19,21,22 and is an
important tract connecting orbitofrontal cortex and ante-
rior temporal lobes.
Different patterns of white matter change were
associated with different FTD subtypes. In MAPT muta-
tion carriers, the most robust changes were within bilat-
eral uncinate fasciculus, bilateral paracallosal and
parahippocampal cingulum, and the body of the corpus
callosum; in the C9ORF72 mutation carriers, within cor-
pus callosum and right paracallosal cingulum bundle;
and in sporadic bvFTD, within the bilateral paracallosal
cingulum bundle. MAPT mutation carriers were the only
FIGURE 2: Plots of each participant’s fractional anisotropy (FA) over time within subdivisions of the corpus callosum (CC). Each
line represents a single subject, with behavioral variant frontotemporal dementia (bvFTD) participants across the top and con-
trols along the bottom. Red dashed lines indicate the mean trajectory. [Color figure can be viewed in the online issue, which is
available at www.annalsofneurology.org.]
ANNALS of Neurology
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group to have significant change over time within both
right and left uncinate fasciculus, with a high burden of
white matter change occurring in medial temporal lobe
regions. Breakdown of these tracts is biologically plausi-
ble, given that these tracts link gray matter structures
that show preferentially more atrophy in affected MAPT
TABLE 5. Sample Size Estimatesa per Treatment Arm of a Clinical Trial Comparing 3 Different Outcome
Measures to Detect a 20 to 50% Reduction in Rates of Change
DTI Change, %/yr BBSI, ml/yr Change in Graded
Naming Test
Right Cingulum
Bundle
Right Uncinate
Fasciculus
% Change FA MD RD AX
20 276 1,031 531 1,229 507 1,524
30 123 459 236 546 226 685
40 69 258 133 308 127 381
50 45 165 85 197 82 246
Sample size estimates have been adjusted for control rates of change.
ab5 80%, a5 0.05.
AX5 axial diffusivity; BBSI5 brain boundary shift integral (a measure of whole brain atrophy); DTI5 diffusion tensor imaging;
FA5 fractional anisotropy; MD5mean diffusivity; RD5 radial diffusivity.
FIGURE 3: Plots of each participant’s fractional anisotropy (FA) over time within the uncinate fasciculus and paracallosal (PC)
cingulum bundle. Each line represents a single subject, with behavioral variant frontotemporal dementia (bvFTD) participants
along the left and controls along the right. Red dashed lines indicate the mean trajectory. L5 left; R5 right. [Color figure can
be viewed in the online issue, which is available at www.annalsofneurology.org.]
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mutation carriers.30 Uncinate fasciculus pathology has
also been demonstrated in presymptomatic MAPT muta-
tion carriers.2 Furthermore, breakdown of these tracts
may account for deficits in cognitive processes such as
episodic memory, semantic knowledge, and emotion
processing seen in MAPT mutation carriers.23,31
Although interpretation of change within the C9ORF72
group must be viewed in terms of the small sample size,
it is of interest that only this group showed significant
difference in bilateral superior cerebellar peduncles cross-
sectionally and neared significance (p5 0.06) longitudi-
nally. This might be surprising for a “frontotemporal”
dementia; however, this finding is consistent with other
data suggesting that changes within the cerebellum and
associated structures may be a particular hallmark of
C9ORF72 mutation carriers.5,32,33 In the sporadic
bvFTD group, bilateral paracallosal cingulum was the
primary region of interest affected, which is in keeping
with the broader group level finding. The heterogeneity
of the group could provide a possible explanation for the
emergence of a more limited profile of white matter
change in this group. However, it is noteworthy that the
paracallosal cingulum displayed significant differences
from controls across subgroups both cross-sectionally and
longitudinally. This suggests that damage to these fibers
is common across the spectrum of bvFTD, making it a
potentially appealing tract to study longitudinally.
An important issue that remains poorly understood
is the choice of DTI metric to detect and track white mat-
ter change. To date, most longitudinal DTI studies have
reported only changes in FA,34,35 although more recently
studies have also reported on changes in mean diffusiv-
ity.14,36 The current study compared the performance of a
range of DTI metrics and suggests that the optimal region
of interest and DTI metric may differ cross-sectionally and
longitudinally. From the cross-sectional data, RD within
the right uncinate fasciculus performed best, whereas FA
change within the right paracallosal cingulum bundle per-
formed best longitudinally and yielded the lowest sample
size estimation. These differences may in part be explained
by variations in disease neurobiology and tract anatomy.
Changes in RD and AX are thought to reflect local
changes in myelination and axonal damage, respectively,
whereas FA, a composite of these measures, reflects
changes in the overall direction of diffusion reflecting
more general white matter integrity. RD and AX may
have superior ability to detect focal white matter pathol-
ogy, making them sensitive cross-sectional metrics. The
longitudinal changes detected may reflect Wallerian degen-
eration, a process commonly seen in a range of neurodege-
nerative disorders,37 which may be better detected by
FA.38 However, we do not argue that FA is the only met-
ric to capture change, particularly as FA values are deter-
mined to some degree by changes in RD. The
performance of particular DTI metrics is likely affected by
individual patient variability, particularly relevant to
bvFTD given its pathological heterogeneity, which may
result in variable trajectories of disease progression (see
Figs 2 and 3). It is possible that certain white matter struc-
tures are more suited to longitudinal measurements than
others, perhaps due to their orientation or size, thus allow-
ing better registration. For example, change within the
genu and body of the corpus callosum appeared more sta-
ble in control participants, whereas in other structures the
trajectory of change was more variable (see Figs 2 and 3).
Understanding how disease neurobiology results in
specific changes to DTI metrics will require further studies
with larger pathologically confirmed cohorts, including the
progranulin genetic subtype, which the current study lacks.
Larger studies will be required to confirm these data as well
as to examine changes within other white matter structures
not included here. Further improvements to image acquisi-
tion and analysis through the use of multishell acquisitions
may improve spatial resolution of the data and provide
greater information on white matter integrity.39
We have demonstrated that a within-subject mea-
sure of DTI change is a potentially useful disease bio-
marker with the ability to detect greater differences
across white matter regions compared with cross-sectional
measures. This, coupled with lower sample size require-
ments, suggests that longitudinal DTI may be an impor-
tant biomarker for disease monitoring with particular
implications for future clinical trials.
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